Amiocor

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amiocor

Property Description
Active ingredient Amiodarone Hydrochloride
Form Tablet (oral) and Solution for Injection (intravenous)
Pharmacological class Antiarrhythmic Drug (Vaughan Williams Class III)
Common use Heart rhythm stabilization
Origin Synthetic, Benzofuran Derivative

What Type of Medicine is Amiocor? (Classification and Identity)

Amiocor is a brand-name, synthetic prescription-only medicinal product whose active ingredient is Amiodarone Hydrochloride. This agent is clinically recognized as a potent Antiarrhythmic Drug. It is predominantly categorized within the Vaughan Williams Class III classification, which primarily denotes its action on potassium channels to prolong the electrical recovery phase of cardiac cells. Amiodarone is also chemically distinct as an iodine-rich Benzofuran Derivative. This unique classification is foundational to its general purpose, establishing it as a highly effective tool for controlling complex, sustained electrical disturbances in the heart.

Composition and Available Forms of Amiodarone Hydrochloride

The medication is a single active ingredient product based exclusively on Amiodarone Hydrochloride. It is supplied for use in two key pharmaceutical forms: as a solid tablet for oral administration and as a sterile solution for injection for intravenous use. The solution for injection is a complex formulation that requires the inclusion of solubilizing agents, such as polysorbate 80, in its aqueous vehicle to ensure the active substance remains suitably dispersed. The dual availability allows for clinical use in both planned long-term rhythm management and in acute, monitored settings.

The General Purpose of Amiocor in Heart Health

The core therapeutic purpose of Amiocor is to provide essential Heartbeat Stabilization by acting as an effective membrane stabilizer on the cardiac electrical system. Its mechanism creates an Electrical Reset function by delaying the repolarization process, which makes the heart tissue resistant to re-entry electrical circuits. This action is generally intended to aid in controlling and preventing episodes of dangerous, excessively rapid, or irregular electrical activity, collectively termed cardiac arrhythmias. By prolonging the refractory period of the heart tissue, Amiocor helps to establish and maintain a steady, more predictable heart rhythm, a critical outcome in rhythm-control therapy.

What side effects are possible with Amiocor?

Amiocor: Possible Side Effects and Safety Information

This information describes the documented adverse reactions and safety profile of Amiocor, based on official regulatory sources such as the FDA and EMA. It is not instructional or advisory.


Frequency-Classified Adverse Reactions

Adverse reactions are classified by frequency of occurrence:

Classification Examples of Documented Side Effects
Very Common (1/10) Corneal microdeposits, isolated increase in liver transaminases, gastrointestinal issues (nausea, vomiting).
Common (1/100 to <1/10) Bradycardia, Hypothyroidism, Hyperthyroidism, Photosensitivity, Pulmonary Toxicity.
Uncommon (1/1,000 to <1/100) Peripheral sensorimotor neuropathy, conduction disturbances.
Very Rare (<1/10,000) Optic neuropathy/neuritis (potential for blindness), chronic liver disease (cirrhosis).

Serious Adverse Reactions and Safety Focus

Regulatory documents emphasize specific serious adverse reactions:

  • Pulmonary Toxicity: Including interstitial pneumonitis and fibrosis, which can be fatal.
  • Hepatic Injury: Acute and chronic liver disorders, including liver failure, which can also be fatal.
  • Thyroid Dysfunction: Both hypothyroidism and hyperthyroidism are common, requiring monitoring.
  • Visual Impairment: Optic neuropathy/neuritis, which may lead to permanent blindness.

Safety Constraints and Monitoring

  • Mandatory Monitoring: Regular monitoring of Liver Function Tests and Thyroid Function ( usTSH) is required before and during therapy.
  • Persistence of Effects: Due to the drug's long half-life, adverse reactions and drug interactions may persist for several weeks after the medicine is stopped.
  • Contraindications: Amiocor is contraindicated in certain cardiac conduction defects (without a pacemaker) and in cardiogenic shock.
  • Population Safety: Use is generally not recommended during pregnancy and lactation due to potential fetal/neonatal harm.

Overdose and Emergency Response

Overdose and When to Seek Help

Immediate medical attention is necessary in the event of a suspected Amiocor (amiodarone) overdose. Due to the drug's properties, an overdose can have a serious or even fatal outcome, primarily related to its profound effects on the heart.

Documented Overdose Symptoms

Symptoms reported in cases of amiodarone overdose typically involve the cardiovascular system and the central nervous system. These may include:

  • Cardiovascular: Significantly slow heartbeat (bradycardia), low blood pressure (hypotension), cardiac shock, or heart block (AV block).
  • General/Other: Nausea, lightheadedness, dizziness, fainting, and blurred vision.

Emergency Actions and Medical Attention

If an overdose is suspected, you must contact a healthcare professional, a hospital emergency department, or a regional Poison Control Centre immediately, even if no symptoms are currently present.

Medical intervention focuses on supportive treatment, which may involve the use of fluids, vasopressors, or positive inotropic agents to manage blood pressure and circulation. In cases of heart block, temporary cardiac pacing may be required. Amiodarone and its main metabolite are not effectively removed by dialysis.

Therapeutic Uses of Amiocor

Quick Facts: Amiocor’s Therapeutic Domains

  • Helps manage recurrent ventricular fibrillation (VF).
  • Supports the treatment of unstable ventricular tachycardia (VT).
  • Used when other medications have not provided adequate results.
  • Assists in the rhythm control of certain supraventricular tachyarrhythmias, such as atrial fibrillation.

Amiocor is a prescribed therapeutic agent employed to help manage specific, serious heart rhythm disturbances. Its primary role involves supporting the treatment of life-threatening and frequently recurring ventricular arrhythmias, including ventricular fibrillation and unstable ventricular tachycardia.

For patients with these documented conditions, Amiocor is administered when the condition has not responded to other available antiarrhythmic treatments or when a patient cannot tolerate those alternatives. The clinical goal is to assist in controlling the abnormal electrical activity that contributes to these rhythms, which may help maintain a more regulated heart function.

In clinical practice, this agent is also utilized to facilitate the rhythm management of other irregular heartbeats, such as atrial fibrillation, outside of its primary indications, based on healthcare provider judgment. Treatment with Amiocor is generally reserved for serious cardiac concerns due to its clinical profile.

Eligibility and Restrictions for Use

Eligibility Scope

Amiocor (Amiodarone Hydrochloride) is officially restricted to adult patients with documented, life-threatening arrhythmias. Use in pediatric patients is not established, and regulatory bodies generally advise against its use in this age group.

Eligibility Status
Allowed Adults with severe, recurrent ventricular arrhythmias refractory to other treatments.
Not Recommended Pediatric patients, pregnant or breastfeeding individuals, and those with severe hepatic failure.
Contraindicated Patients with specific unmanaged electrical abnormalities (e.g., sick sinus syndrome or AV block without a pacemaker) or overt hyperthyroidism.

Absolute Contraindications officially prohibit use in individuals with known hypersensitivity to the drug or iodine, or with certain cardiovascular conditions like cardiogenic shock or marked sinus bradycardia not managed by a pacemaker. The medicine is also strictly contraindicated during pregnancy and lactation due to the risk of fetal and infant harm, particularly to the thyroid.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Amiocor (Amiodarone) has a highly significant interaction profile due to its impact on metabolic enzymes and drug transporters. The regulatory documentation strictly defines restrictions on its co-administration with numerous substances.


Pharmacokinetic Interactions

Amiocor is documented as a major inhibitor of several Cytochrome P450 (CYP) enzymes, primarily CYP2C9, CYP2D6, and CYP3A4. This inhibition increases the systemic exposure of co-administered drugs that are substrates for these enzymes. Amiocor also inhibits the drug efflux transporter P-glycoprotein (P-gp), leading to elevated concentrations of P-gp substrate medications, such as Digoxin and certain anticoagulants.

  • Resulting Constraint: Official labeling mandates necessary dose reductions for many commonly co-administered drugs, including Warfarin, Simvastatin, and Digoxin, due to the risk of toxicity from increased concentrations of the interacting medication.

Pharmacodynamic and Contraindicated Interactions

Co-administration with substances that share effects on cardiac rhythm is a critical restriction. Amiocor should not be used with drugs known to cause QT interval prolongation due to the significantly increased risk of fatal arrhythmias like Torsades de Pointes.

  • Contraindication Example: Specific combinations, such as certain Direct Acting Antiviral (DAA) regimens for Hepatitis C (e.g., those containing Sofosbuvir), are explicitly contraindicated or require specialized monitoring due to documented severe bradycardia.

Food and Beverage Restrictions

Consumption of Grapefruit Juice is explicitly restricted. Regulatory documents note that grapefruit juice inhibits the metabolism of Amiocor, leading to an increased systemic concentration of Amiocor itself.

Mechanism of Action

Stabilizing the Heart's Electrical Recovery

Amiocor primarily modulates cardiac electrical activity by acting as a non-competitive blocker of multiple ion channels. Its most prominent action is the inhibition of potassium channels (particularly the delayed rectifier current, I Kr), which significantly prolongs the repolarization phase of the action potential. This lengthens the effective refractory period (ERP) in cardiac tissues. This physiological change interrupts the abnormal electrical loops that perpetuate rapid, disorganized heart activity, thereby contributing to a more uniform rate of electrical impulse transmission.


Systemic Modulation of Excitation

A secondary mechanism involves non-competitive antagonism of beta-adrenergic receptors, interfering with the influence of sympathetic nervous system signals like adrenaline. This action on autonomic control results in a slowing of the heart rate (negative chronotropy) and a decrease in the force of muscle contraction (negative inotropy). Furthermore, the molecule's high lipophilicity leads to extensive tissue accumulation, resulting in a long biological half-life and sustained presence. This characteristic, along with its modulation of thyroid hormone pathways, contributes to the comprehensive and prolonged adjustment of cardiac function.

Dosage and Administration Information

How to Use Amiodarone (Amiocor) — Administration Guidelines

Administration of Amiodarone follows specific protocols based on the prescribed route and phase of treatment. The drug is available in two forms: oral tablets and an intravenous (IV) solution.


Dosing and Route

Administration Type Dosing Schedule Summary Administration Notes
Oral Tablet (PO) Involves high-dose loading (800 mg to 1600 mg daily) followed by a long-term maintenance dose (e.g., 400 mg daily). Oral tablets must be taken consistently with meals to aid absorption. Doses greater than 1000 mg daily are often divided.
IV Solution Used for initiation or urgent care. Starts with a rapid 150 mg loading infusion, followed by a slower continuous maintenance infusion (e.g., 0.5 mg/min). IV concentrations greater than 2 mg/mL require a central venous catheter.

Procedural Instructions

  1. Preparation (IV): The injectable solution must be diluted in 5% Dextrose in Water (D5W). For infusions lasting longer than two hours, specialized glass or polyolefin containers must be used.
  2. Infusion: IV Amiodarone must be administered via a volumetric infusion pump using an in-line filter to control the rate and ensure proper delivery.
  3. Transition: Patients receiving IV therapy for more than two to three weeks should be transitioned to a lower oral maintenance dose based on the duration of IV exposure.

The overall use protocol involves a structured, two-phase treatment (loading then maintenance) tailored to the administration route, requiring specific equipment and instruction (e.g., consistent food intake for oral tablets).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Drug X

Evidence for use in Type 2 Diabetes Mellitus (T2DM)

Research exploring the use of Drug X for Type 2 Diabetes has primarily relied on Randomized Controlled Trials (RCTs), which are a common study design used in research. These trials were evaluated in adult populations with Type 2 Diabetes, comparing Drug X against a placebo or against other existing anti-diabetic medications. This body of research was studied for specific outcomes related to systemic or functional imbalance, such as changes in the level of HbA1c (a measure of average blood sugar levels) and shifts in body weight. Studies monitored both short-term (lasting a few months) and intermediate changes (up to two years).

The research also included a post-hoc analysis—an additional study of data already collected—from a large-scale cardiovascular outcomes trial (CVOT). This trial research explored cardiovascular-related outcomes over defined time intervals in a population of adults with Type 2 Diabetes who had pre-existing heart disease or multiple cardiovascular risk factors.

Evidence for use in Chronic Weight Management

The evidence structure for chronic weight management consists primarily of dedicated, large Phase III Randomized Controlled Trials (RCTs). These studies were applied in populations characterized by functional limitations related to weight (adults with obesity or those classified as overweight with a related comorbidity, excluding diabetes). The research examined outcomes related to physical discomfort and daily functioning. Specifically, research examined the percentage of change in body weight from baseline. The research also monitored changes in cardiometabolic risk markers, such as blood pressure and cholesterol levels.

Studies explored changes measured over an intermediate duration, typically lasting around 68 to 78 weeks. Findings describe the measurements of body weight and how these changed in the observed populations during the study period.

Long-term Studies and Follow-up

Research has explored outcomes over extended periods, with follow-up durations ranging from intermediate (around one to two years) for blood sugar and weight measures, up to a median of 3.5 years for the cardiovascular safety data collected in the dedicated CVOT in high-risk patients with Type 2 Diabetes. However, follow-up durations for many outcomes were limited, meaning that long-term effects on sustained weight loss, continued blood sugar control, and overall health outcomes over many years are not well characterized.

What is Still Uncertain About Drug X

Research highlights what is known—and what is still uncertain. Findings were mixed or inconsistent across studies for some secondary outcomes. Key research limitations include the long-term perspective: there is limited information for long-term outcomes that span many years. The evidence quality varies across studies, and many subgroup findings are uncertain due to small sample sizes within those specific groups. Research provides context but not individual predictions; study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Once-Weekly Semaglutide in Adults With Overweight or Obesity (STEP 1)
  2. Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results from the SOUL Randomized Trial

Frequently Asked Questions (FAQ)

Common questions about Amiocor (FAQ)


Q: Why do doctors prescribe Amiocor instead of other medicines for the same condition?

A: Amiocor is classified as a Vaughan Williams Class III antiarrhythmic. Official information describes it as primarily working by blocking potassium channels, which stabilizes the heart’s electrical activity. Because of its potent effects, it is typically indicated for use in managing life-threatening irregular heart rhythms that have not adequately responded to other available treatments.


Q: Is Amiocor safe to take if I have liver problems?

A: Official documentation states that Amiocor is generally not recommended for individuals with severe liver failure. The product information mandates that liver function tests must be regularly monitored both before starting and throughout treatment. This is because adverse reactions related to liver injury are known to occur.


Q: What is the risk of having a serious side effect with Amiocor?

A: Regulatory documents emphasize the risk of serious adverse reactions, including pulmonary toxicity (lung injury) and hepatic injury (liver injury), which have been documented as potentially fatal. Due to these risks, mandatory monitoring of both liver and thyroid function tests is required during treatment. These official requirements are in place to manage known safety concerns.


Q: Do studies support the long-term use of Amiocor?

A: The official administration guidelines describe a structured approach involving an initial dosing period followed by a long-term maintenance phase. While this implies prolonged use, evidence indicates that outcomes spanning many years are not well characterized in the long-term studies that have been conducted.


Q: What are the most common reasons someone would stop taking Amiocor?

A: Official sources describe a number of adverse reactions that may lead to the discontinuation of the drug. The most frequently cited reasons in regulatory documents relate to serious safety concerns, such as the onset of pulmonary toxicity, hepatic injury, or thyroid dysfunction (both underactive and overactive thyroid).


Q: Why is Amiocor sometimes called by a different name?

A: Amiocor is the brand name used for this medication. The medicine’s active ingredient is Amiodarone Hydrochloride, which is often used as the generic name. Therefore, the medication is commonly referred to by both its brand and active ingredient name.


Q: What information is available about the effectiveness of Amiocor?

A: Official information states that Amiocor is an approved antiarrhythmic drug. Its purpose is to stabilize heart rhythm by controlling and preventing episodes of dangerous, rapid, or irregular electrical activity, which are collectively known as cardiac arrhythmias.


Q: What are the signs of a possible allergic reaction to Amiocor?

A: Official documents note that Amiocor is contraindicated if there is a known hypersensitivity (allergy) to the drug or to iodine. While incidence is not always known, signs of a severe allergic-type reaction listed in the product information include blistering, peeling, or loosening of the skin.


Q: Does Amiocor have to be taken at the exact same time every day?

A: Regulatory administration guidelines emphasize that oral tablets must be taken consistently with meals to enhance absorption. While maintaining a routine is often a part of consistent use, the specific requirement for taking the drug at the exact same hour every day is not explicitly stated in official documents.


Q: Does research show Amiocor is generally well-tolerated?

A: Official safety profiles document the tolerance of the drug through the frequency of adverse reactions. This medication is associated with a high incidence of adverse effects, including very common effects like corneal microdeposits, and serious common effects like pulmonary toxicity. These factors necessitate the mandatory monitoring outlined in official guidelines.


Q: Does Amiocor affect blood pressure?

A: Yes, official product information indicates that Amiocor can affect blood pressure. Hypotension, which is low blood pressure, is documented as the most common adverse effect when the drug is administered intravenously.


Q: How long does it typically take for Amiocor to start working?

A: The time it takes for the therapeutic effect to begin varies. Following oral administration, the onset of action may begin within a few days but often takes one to three weeks to be fully established, even when a loading dose schedule is used.


Q: Can Amiocor cause weight gain?

A: Weight gain is listed in official documentation as an uncommon side effect, meaning it occurs in less than one in 100 patients. This effect is sometimes associated with the drug's known ability to modulate thyroid function.


Q: What happens if I miss a day of taking Amiocor?

A: General regulatory guidance suggests that if a dose is missed, and it is nearly time for the next scheduled dose, the prior dose is typically omitted to prevent accidentally taking more than the prescribed amount.


Q: Can I take painkillers like ibuprofen while using Amiocor?

A: Official regulatory sources do not list a direct drug-drug interaction with common nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. However, co-administration is associated with a potential for general side effects, such as gastrointestinal irritation.


Q: Is it normal to feel dizzy when starting Amiocor?

A: Yes, official safety information lists dizziness as a side effect that can occur with the use of Amiodarone. This is considered a more common reaction.


Q: Does Amiocor interact with alcohol?

A: Regulatory-based safety information suggests that limiting alcohol consumption may be necessary due to alcohol's potential to increase the chance of liver-related problems, which is a known safety concern with Amiocor.


Q: Is there a link between Amiocor and hair loss?

A: Hair thinning has been noted in post-marketing reports for this drug, although it is not a frequently occurring side effect. It is sometimes understood as an effect potentially related to the drug's known impact on thyroid function.


Q: Can people with kidney disease use Amiocor?

A: Official clinical guidance indicates that Amiodarone is primarily metabolized by the liver rather than the kidneys. Therefore, it can be used in individuals with kidney disease or those on hemodialysis, though other precautions and monitoring are still necessary.


Q: What if I take Amiocor and feel no difference?

A: The drug’s main purpose is to provide electrical stabilization to the heart, which is a physiological change that the patient may not immediately feel. The onset of this therapeutic effect can take one to three weeks to fully materialize.


Q: Can Amiocor cause sleeping problems or insomnia?

A: Yes, official safety documentation lists both sleep disorders and insomnia as common side effects. This means they are documented to occur in at least 1 out of every 100 patients.


Q: Is it safe to drive while taking Amiocor?

A: Regulatory information notes that this medication may cause certain side effects, such as dizziness, blurred vision, or a slow heart rate. These documented effects may impair a person's ability to safely perform skilled activities like driving or operating machinery.


Q: Does Amiocor interact with herbal supplements like St. John's Wort?

A: Official information indicates that this herbal supplement may decrease the intended effects of Amiocor, and the combination is generally not recommended in product documentation.


Q: Can Amiocor affect my mood or cause depression?

A: Official product information includes documentation of psychiatric adverse reactions, such as depression and general mood changes. These effects are generally listed in case reports and post-marketing data, suggesting they are considered uncommon.


Q: Is it true that Amiocor is prescribed for more than one heart condition?

A: Yes, the official use of Amiocor is described as treating severe ventricular arrhythmias (such as VT/VF). Additionally, it is often employed in clinical practice for controlling various other types of irregular heart rhythms, including supraventricular arrhythmias like atrial fibrillation.


Q: Does Amiocor have any known interactions with commonly used cold medicines?

A: Official drug interaction resources indicate a potential interaction with a common ingredient in cold medicines. Amiocor can increase the levels of dextromethorphan, a frequent cough suppressant, which may increase the risk of side effects like dizziness or drowsiness from that cold medicine.


Q: What happens if I stop taking Amiocor suddenly?

A: Due to the risk of arrhythmia recurrence and its long half-life, official guidance states that stopping treatment abruptly is generally not recommended and that close medical monitoring is required upon cessation.


Q: Is Amiocor available as a generic medicine?

A: Yes, the active ingredient in Amiocor, which is Amiodarone Hydrochloride, is available as a generic medicine.


Q: What is the consensus among medical experts about Amiocor?

A: Official clinical guidelines and expert consensus describe Amiodarone as a well-established and accepted antiarrhythmic medication. It is reserved for the control of life-threatening irregular heart rhythms that have been resistant to other therapeutic agents.


Q: How long is Amiocor usually prescribed for?

A: For the management of chronic conditions, official guidance states that the treatment duration often continues long-term. The decision to discontinue is based on a patient’s specific condition and the development of side effects, rather than a fixed maximum duration.


Q: What is the maximum duration of treatment with Amiocor mentioned in official documents?

A: Official prescribing information does not define a maximum duration for long-term oral maintenance therapy. However, the documentation notes that the intravenous form of the drug has limited clinical experience when administered for longer than two to three weeks.

How should Amiocor be stored and disposed of?

How to Store and Dispose of Amiocor?

Strict adherence to regulatory guidelines ensures the stability and safety of Amiocor (Amiodarone Hydrochloride).


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Protect from light and keep away from excessive heat and moisture.
Container Keep in the original container, tightly closed, and out of the reach of children.
Injection Do not freeze or refrigerate the concentrate. The diluted solution has a limited use-time (e.g., 24 hours).

Disposal Instructions

Amiocor must not be disposed of using household trash or wastewater (flushed down the sink/toilet). Unused or expired medication must be handled according to local regulatory requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amiocor found in:

A-Z Index: